NasdaqGM - Nasdaq Real Time Price • USD
Sage Therapeutics, Inc. (SAGE)
As of 2:22 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 18 | 18 | 20 | 19 |
| Avg. Estimate | -1.65 | -1.64 | -6.39 | -4.84 |
| Low Estimate | -2.16 | -2 | -7.98 | -7.09 |
| High Estimate | -1.26 | -1.02 | -3.96 | 2.56 |
| Year Ago EPS | -2.46 | -2.68 | -9.05 | -6.39 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 17 | 19 | 19 |
| Avg. Estimate | 5.66M | 7.1M | 34.24M | 137.45M |
| Low Estimate | 2.12M | 2.45M | 14.14M | 35.57M |
| High Estimate | 15.08M | 15.58M | 80.22M | 528.73M |
| Year Ago Sales | 2.41M | 2.47M | 86.45M | 34.24M |
| Sales Growth (year/est) | 134.90% | 187.40% | -60.40% | 301.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -2.5 | -2.55 | -2.73 | -1.28 |
| EPS Actual | -2.46 | -2.68 | -3.37 | -0.55 |
| Difference | 0.04 | -0.13 | -0.64 | 0.73 |
| Surprise % | 1.60% | -5.10% | -23.40% | 57.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.65 | -1.64 | -6.39 | -4.84 |
| 7 Days Ago | -1.63 | -1.6 | -6.22 | -4.72 |
| 30 Days Ago | -1.6 | -1.58 | -6.22 | -4.76 |
| 60 Days Ago | -1.65 | -1.63 | -6.54 | -4.99 |
| 90 Days Ago | -1.6 | -1.78 | -6.2 | -5.45 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | 2 | 2 | 2 |
| Up Last 30 Days | 3 | 4 | 5 | 5 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 3 | 2 |
Growth Estimates
| CURRENCY IN USD | SAGE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 32.90% | -- | -- | 0.80% |
| Next Qtr. | 38.80% | -- | -- | 9.60% |
| Current Year | 29.40% | -- | -- | 4.50% |
| Next Year | 24.30% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 16.80% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Scotiabank: Sector Outperform to Sector Outperform | 4/18/2024 |
| Maintains | Oppenheimer: Perform to Perform | 4/18/2024 |
| Maintains | TD Cowen: Buy to Buy | 4/18/2024 |
| Reiterates | Needham: Hold | 4/18/2024 |
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 4/17/2024 |
| Reiterates | Wedbush: Neutral to Neutral | 4/17/2024 |
Related Tickers
MRNS Marinus Pharmaceuticals, Inc.
1.4000
-0.71%
RARE Ultragenyx Pharmaceutical Inc.
41.47
-4.40%
NMRA Neumora Therapeutics, Inc.
10.24
-2.94%
BHVN Biohaven Ltd.
38.40
-8.92%
APLS Apellis Pharmaceuticals, Inc.
47.25
-0.55%
VNDA Vanda Pharmaceuticals Inc.
5.20
+4.63%
AMLX Amylyx Pharmaceuticals, Inc.
1.8850
-4.80%
ACAD ACADIA Pharmaceuticals Inc.
16.87
-1.17%
BCRX BioCryst Pharmaceuticals, Inc.
4.2950
-4.56%
CGEM Cullinan Therapeutics, Inc.
15.78
-12.62%